Fananserin is primarily investigated for its potential application in the field of neuropharmacology, particularly as an antipsychotic agent. It functions as a selective antagonist for serotonin and dopamine receptors, which are critical in the modulation of mood, cognition, and behavior. This makes it a candidate for the treatment of psychiatric disorders such as schizophrenia, where dysregulation of these neurotransmitters is often observed. Additionally, its receptor activity suggests potential utility in managing conditions like anxiety and depression, although further research is required to fully establish its efficacy and safety in these areas. The compound's ability to modulate neurotransmitter systems also opens avenues for exploring its use in other neurological conditions where serotonin and dopamine play a key role.